Advancements in biologic therapy in eosinophilic asthma

References

• Corren J, Parnes JR, Wang L, et al. Tezepelumab in adults with uncontrolled asthma. N Engl J Med. 2017;377(10):936–946. doi: 10.1056/NEJMoa1704064
   PubMed Web of Science ®Google Scholar
• Taunk ST, Cardet JC, Ledford DK. Clinical implications of asthma endotypes and phenotypes. Allergy Asthma Proc. 2022 Sep 1;43(5):375–382. doi: 10.2500/aap.2022.43.220047
   PubMed Web of Science ®Google Scholar
• Kuruvilla ME, Lee F-H, Lee GB. Understanding Asthma Phenotypes, Endotypes, and Mechanisms of Disease. Clin Rev Allerg Immunol. 2019;56(2):219–233. doi: 10.1007/s12016-018-8712-1
   PubMed Web of Science ®Google Scholar
• Bakakos A, Loukides S, Bakakos P. Severe Eosinophilic Asthma. J Clin Med. 2019;8(9):1375. doi: 10.3390/jcm8091375
   PubMed Web of Science ®Google Scholar
• Pelaia C, Paoletti G, Puggioni F, et al. Interleukin-5 in the Pathophysiology of Severe Asthma. Front Physiol. 2019;10:10. doi: 10.3389/fphys.2019.01514
   PubMed Web of Science ®Google Scholar
• Patel SS, Casale TB, Cardet JC. Biological therapies for eosinophilic asthma. Expert Opin Biol Ther. 2018;18(7):747–754. doi: 10.1080/14712598.2018.1492540
   PubMed Web of Science ®Google Scholar
• Ortega HG, Liu MC, Pavord ID, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014;371(13):1198–1207. doi: 10.1056/NEJMoa1403290
   PubMed Web of Science ®Google Scholar
• Bel EH, Wenzel SE, Thompson PJ, et al. Oral glucocorticoid-sparing effect of Mepolizumab in eosinophilic asthma. N Engl J Med. 2014;371(13):1189–1197. doi: 10.1056/NEJMoa1403291
   PubMed Web of Science ®Google Scholar
• Kim T. Validity and Reliability of the St. George’s Respiratory Questionnaire in Asthmatic Patients. J allergy clin immunol. 2008;121(2):S80–S80. doi: 10.1016/j.jaci.2007.12.318
   Web of Science ®Google Scholar
• Chupp GL, Bradford ES, Albers FC, et al. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial. Lancet Respir Med. 2017 May;5(5):390–400.
   PubMed Web of Science ®Google Scholar
• Lugogo N, Domingo C, Chanez P, et al. Long-term Efficacy and Safety of Mepolizumab in Patients with Severe Eosinophilic Asthma: A Multi-center, Open-label, Phase IIIb Study. Clin Ther. 2016;38(9):2058–2070.e1. doi: 10.1016/j.clinthera.2016.07.010
   PubMed Web of Science ®Google Scholar
• Khurana S, Brusselle GG, Bel EH, et al. Long-term Safety and clinical benefit of mepolizumab in patients with the most severe eosinophilic asthma: the COSMEX Study. Clin Ther. 2019;41(10):2041–2056.e5. doi: 10.1016/j.clinthera.2019.07.007
   PubMed Web of Science ®Google Scholar
• Moore WC, Kornmann O, Humbert M, et al. Stopping versus continuing long-term mepolizumab treatment in severe eosinophilic asthma (COMET study). Eur Respir J. 2022 Jan;59(1):2100396.
   PubMed Web of Science ®Google Scholar
• Casale T, Molfino NA, Silver J, et al. Real-world effectiveness of mepolizumab in patients with severe asthma and associated comorbidities. Ann Allergy Asthma Immunol. 2021;127(3):354–362.e2. doi: 10.1016/j.anai.2021.05.021.
   PubMed Web of Science ®Google Scholar
• Pilette C, Canonica GW, Chaudhuri R, et al. REALITI-A study: real-world oral corticosteroid-sparing effect of mepolizumab in severe asthma. The Journal Of Allergy And Clinical Immunology In Practice. 2022;10(10):2646–2656. doi: 10.1016/j.jaip.2022.05.042
   PubMed Web of Science ®Google Scholar
• Liu MC, Bagnasco D, Matucci A, et al. Mepolizumab in patients with severe asthma and comorbidities: 1-Year REALITI-A Analysis. J Allergy Clin Immunol Pract. 2023 Jul 26;11(12):3650–3661.e3. doi: 10.1016/j.jaip.2023.07.024
   PubMed Web of Science ®Google Scholar
• Yang F, Busby J, Heaney LG, et al. Corticosteroid responsiveness following mepolizumab in severe eosinophilic asthma—a randomized, placebo-controlled crossover trial (MAPLE). J Allergy Clin Immunol Pract. 2022 Nov;10(11):2925–2934.e12.
   PubMed Web of Science ®Google Scholar
• Hom S, Pisano M. Reslizumab (Cinqair): an interleukin-5 antagonist for severe asthma of the eosinophilic phenotype. Pharm Ther. 2017;42(9):564–568.
   Google Scholar
• Castro M, Zangrilli J, Wechsler ME. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med. 2015;3(5):355–366. doi: 10.1016/S2213-2600(15)00042-9
   PubMed Web of Science ®Google Scholar
• Nair P, Bardin P, Humbert M, et al. Efficacy of Intravenous reslizumab in oral corticosteroid-dependent asthma. J Allergy Clin Immunol Pract. 2020 Feb;8(2):555–564.
   PubMed Web of Science ®Google Scholar
• Wechsler ME, Hickey L, Garin M, et al. Efficacy of Reslizumab treatment in exacerbation-prone patients with severe eosinophilic asthma. J Allergy Clin Immunol Pract. 2020; Nov.8(10):3434–3442 e4. doi: 10.1016/j.jaip.2020.06.009
   PubMed Web of Science ®Google Scholar
• Hashimoto S, Kroes JA, Eger KA, et al. Real-world effectiveness of reslizumab in patients with severe eosinophilic asthma – first initiators and switchers. J Allergy Clin Immunol Pract. 2022 Aug;10(8):2099–2108.e6.
   PubMed Web of Science ®Google Scholar
• Murphy K, Jacobs J, Bjermer L, et al. Long-term safety and efficacy of reslizumab in patients with eosinophilic asthma. J Allergy Clin Immunol Pract. 2017 Nov;5(6):1572–1581 e3.
   PubMed Web of Science ®Google Scholar
• Pelaia C, Calabrese C, Vatrella A, et al. Benralizumab: from the basic mechanism of action to the potential use in the biological therapy of severe eosinophilic asthma. Bio Med Res Int. 2018;2018:1–9. doi: 10.1155/2018/4839230
   Google Scholar
• Tsutomu Y, Mitsuo S, Yoshinori N, et al. Allergic diseases: From bench to clinic - contribution of the discovery of interleukin-5. Cytokine. 2017;98:59–70. doi: 10.1016/j.cyto.2016.11.011
   PubMed Web of Science ®Google Scholar
• Nair P, Wenzel S, Rabe KF, et al. Oral glucocorticoid–sparing effect of benralizumab in severe asthma. N Engl J Med. 2017;376(25):2448–2458. doi: 10.1056/NEJMoa1703501
   PubMed Web of Science ®Google Scholar
• Carstens D, Maselli DJ, Mu F, et al. Real-World Effectiveness Study of Benralizumab for Severe Eosinophilic Asthma: ZEPHYR 2. The Journal Of Allergy And Clinical Immunology In Practice. 2023;11(7):2150–2161.e4. doi: 10.1016/j.jaip.2023.04.029
   PubMed Web of Science ®Google Scholar
• Busse WW, Bleecker ER, FitzGerald JM, et al. Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial. Lancet Respir Med. 2019 Jan;7(1):46–59.
   PubMed Web of Science ®Google Scholar
• Korn S, Bourdin A, Chupp G, et al. Integrated safety and efficacy among patients receiving benralizumab for up to 5 years. J Allergy Clin Immunol. 2021;9(12):4381–4392.e4. doi: 10.1016/j.jaip.2021.07.058
   Web of Science ®Google Scholar
• Segal M, Stokes JR, Casale TB. Anti-Immunoglobulin E Therapy. World Allergy Organ J. 2008;1(10):174–183. doi: 10.1097/WOX.0b013e318187a310
   PubMedGoogle Scholar
• Busse W, Corren J, Lanier BQ, et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol. 2001;108(2):184–190. doi: 10.1067/mai.2001.117880
   PubMed Web of Science ®Google Scholar
• Solèr M, Matz J, Townley R, et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J. 2001;18(2):254–261. doi: 10.1183/09031936.01.00092101
   PubMed Web of Science ®Google Scholar
• Bousquet J, Humbert M, Gibson PG, et al. Real-world effectiveness of omalizumab in severe allergic asthma: a meta-analysis of observational studies. J Allergy Clin Immunol. 2021;9(7):2702–2714. doi: 10.1016/j.jaip.2021.01.011
   Web of Science ®Google Scholar
• Casale TB, Luskin AT, Busse W, et al. Omalizumab effectiveness by biomarker status in patients with asthma: evidence from PROSPERO, a prospective real-world study. J Allergy Clin Immunol. 2019;7(1):156–164.e1. doi: 10.1016/j.jaip.2018.04.043
   Web of Science ®Google Scholar
• Casale TB, Chipps BE, Rosén K, et al. Response to omalizumab using patient enrichment criteria from trials of novel biologics in asthma. Allergy. 2018;73(2):490–497. doi: 10.1111/all.13302
   PubMed Web of Science ®Google Scholar
• Harb H, Chatila T. Mechanisms of Dupilumab. Clin Exp Allergy. 2020;50(1):5–14. doi: 10.1111/cea.13491
   PubMed Web of Science ®Google Scholar
• Thibodeaux Q, Smith MP, Ly K, et al. A review of dupilumab in the treatment of atopic diseases. Human Vaccines Immunother. 2019;15(9):2129–2139. doi: 10.1080/21645515.2019.1582403
   PubMed Web of Science ®Google Scholar
• Corren J, Castro M, O’Riordan T, et al. Dupilumab Efficacy in Patients with Uncontrolled, Moderate-to-Severe Allergic Asthma. J Allergy Clin Immunol Pract. 2020 Feb;8(2):516–526.
   PubMed Web of Science ®Google Scholar
• Wechsler ME, Ford LB, Maspero JF, et al. Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): an open-label extension study. Lancet Respir Med. 2022 Jan;10(1):11–25.
   PubMed Web of Science ®Google Scholar
• Busse WW, Maspero JF, Rabe KF, et al. Liberty Asthma QUEST: Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate Dupilumab Efficacy/Safety in Patients with Uncontrolled, Moderate-to-Severe Asthma. Adv Ther. 2018;35(5):737–748. doi: 10.1007/s12325-018-0702-4
   PubMed Web of Science ®Google Scholar
• Svenningsen S, Kjarsgaard M, Haider E, et al. Effects of dupilumab on mucus plugging and ventilation defects in patients with moderate-to-severe asthma: a randomized, double-blind, placebo-controlled trial. Am J Respir Crit Care Med. 2023 Aug 21;208(9):995–997. doi: 10.1164/rccm.202306-1102LE
   PubMed Web of Science ®Google Scholar
• Gauvreau GM, Bergeron C, Boulet LP, et al. Sounding the alarmins—The role of alarmin cytokines in asthma. Allergy. 2023;78(2):402–417. doi: 10.1111/all.15609
   PubMed Web of Science ®Google Scholar
• Marone G, Spadaro G, Braile M, et al. Tezepelumab: a novel biological therapy for the treatment of severe uncontrolled asthma. Expert Opin Investig Drugs. 2019;28(11):931–940. doi: 10.1080/13543784.2019.1672657
   PubMedGoogle Scholar
• Ko H-K, Cheng S-L, Lin C-H, et al. Blood tryptase and thymic stromal lymphopoietin levels predict the risk of exacerbation in severe asthma. Sci Rep. 2021;11(1). doi: 10.1038/s41598-021-86179-1
   Web of Science ®Google Scholar
• Aschenbrenner D. Tezspire approved for severe asthma. Am J Nurs. 2022;122(5):19–19. doi: 10.1097/01.NAJ.0000830728.15289.9f
   PubMed Web of Science ®Google Scholar
• Corren J, Garcia Gil E, Griffiths JM, et al. Tezepelumab improves patient-reported outcomes in patients with severe, uncontrolled asthma in PATHWAY. Ann Allergy Asthma Immunol. 2021;126(2):187–193. doi: 10.1016/j.anai.2020.10.008
   PubMed Web of Science ®Google Scholar
• Menzies-Gow A, Corren J, Bourdin A, et al. Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med. 2021;384(19):1800–1809. doi: 10.1056/NEJMoa2034975
   PubMed Web of Science ®Google Scholar
• Diver S, Khalfaoui L, Emson C, et al. Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Respir Med. 2021 Nov;9(11):1299–1312.
   PubMed Web of Science ®Google Scholar
• Wechsler ME, Menzies-Gow A, Brightling CE, et al. Evaluation of the oral corticosteroid-sparing effect of tezepelumab in adults with oral corticosteroid-dependent asthma (SOURCE): a randomised, placebo-controlled, phase 3 study. Lancet Respir Med. 2022 Jul;10(7):650–660.
   PubMed Web of Science ®Google Scholar
• Menzies-Gow A, Wechsler ME, Brightling CE, et al. Long-term safety and efficacy of tezepelumab in people with severe, uncontrolled asthma (DESTINATION): a randomised, placebo-controlled extension study. Lancet Respir Med. 2023 May;11(5):425–438.
   PubMed Web of Science ®Google Scholar
• Agache I, Rocha C, Beltran J, et al. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab and omalizumab) for severe allergic asthma: a systematic review for the EAACI Guidelines ‐ recommendations on the use of biologicals in severe asthma. Allergy. 2020;75(5):1043–1057. doi: 10.1111/all.14235
   PubMed Web of Science ®Google Scholar
• Antibody reduces allergic reactions to multiple foods in NIH trial: NIH; 2023. Available from: https://www.nih.gov/news-events/news-releases/antibody-reduces-allergic-reactions-multiple-foods-nih-trial
   Google Scholar
• Wood RA, Togias A, Sicherer SH, et al. Omalizumab for the treatment of multiple food allergies. N Engl J Med. 2024;390(10):889–899. doi: 10.1056/NEJMoa2312382
   PubMedGoogle Scholar
• Loizou D, Enav B, Komlodi-Pasztor E, et al. A Pilot Study of Omalizumab in Eosinophilic Esophagitis. PLOS ONE. 2015;10(3):e0113483. doi: 10.1371/journal.pone.0113483
   PubMed Web of Science ®Google Scholar
• Chan S, Cornelius V, Cro S, et al. Treatment effect of omalizumab on severe pediatric atopic dermatitis: the ADAPT randomized clinical trial. JAMA Pediatr. 2020;174(1):29–37. doi: 10.1001/jamapediatrics.2019.4476
   PubMed Web of Science ®Google Scholar
• Bachert C, Han JK, Desrosiers MY, et al. Efficacy and safety of benralizumab in chronic rhinosinusitis with nasal polyps: a randomized, placebo-controlled trial. J allergy clin immunol. 2022;149(4):1309–1317.e12. doi: 10.1016/j.jaci.2021.08.030
   PubMed Web of Science ®Google Scholar
• Bernstein JA, Singh U, Rao MB, et al. Benralizumab for chronic spontaneous urticaria. N Engl J Med. 2020;383(14):1389–1391. doi: 10.1056/NEJMc2016395
   PubMed Web of Science ®Google Scholar
• Guttman‐Yassky E, Bahadori L, Brooks L, et al. Lack of effect of benralizumab on signs and symptoms of moderate‐to‐severe atopic dermatitis: Results from the phase 2 randomized, double‐blind, placebo‐controlled HILLIER trial. J Eur Acad Dermatol Venereol. 2023;37(10).
   Web of Science ®Google Scholar
• Marc E, Rothenberg M. A Study of Benralizumab in Patients with Eosinophilic Esophagitis (MESSINA). 2020. September 22- 2023, February 06. https://clinicaltrials.gov/study/NCT04543409
   Google Scholar
• Bachert C, Han JK, Desrosiers M, et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet. 2019 Nov 02;394(10209):1638–1650. doi: 10.1016/S0140-6736(19)31881-1
   PubMed Web of Science ®Google Scholar
• Simpson EL, Bieber T, Guttman-Yassky E, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335–2348. doi: 10.1056/NEJMoa1610020
   PubMed Web of Science ®Google Scholar
• Dellon ES, Rothenberg ME, Collins MH, et al. Dupilumab in adults and adolescents with Eosinophilic Esophagitis. N Engl J Med. 2022;387(25):2317–2330. doi: 10.1056/NEJMoa2205982
   PubMed Web of Science ®Google Scholar
• Maurer M, Casale T, Saini S, et al. Dupilumab efficacy in patients with chronic spontaneous urticaria by ige level: liberty-csu cupid study a. Ann Allergy Asthma Immunol. 2022;129(5):S11. doi: 10.1016/j.anai.2022.08.538
   PubMedGoogle Scholar
• Yosipovitch G, Mollanazar N, Ständer S, et al. Dupilumab in patients with prurigo nodularis: two randomized, double-blind, placebo-controlled phase 3 trials. Nature Med. 2023;29(5):1180–1190. doi: 10.1038/s41591-023-02320-9
   PubMed Web of Science ®Google Scholar
• Inc GP. Mepolizumab: full prescribing information. [cited 2024 Apr 21].
   Google Scholar
• Han JK, Bachert C, Fokkens W, et al. Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med. 2021;9(10):1141–1153. doi: 10.1016/S2213-2600(21)00097-7
   PubMed Web of Science ®Google Scholar
• Dellon ES, Peterson KA, Mitlyng BL, et al. Mepolizumab for treatment of adolescents and adults with eosinophilic oesophagitis: a multicentre, randomised, double-blind, placebo-controlled clinical trial. Gut. 2023;72(10):1828–1837. doi: 10.1136/gutjnl-2023-330337
   PubMed Web of Science ®Google Scholar
• Inc TP. CINQAIR (reslizumab) prescribing informatin. [cited 2024 Apr 21].
   Google Scholar
• Kuruvilla ME, Levy J. Efficacy of Reslizumab in eosinophilic chronic sinusitis with nasal polyposis. J allergy clin immunol. 2018;141(2):AB270. doi: 10.1016/j.jaci.2017.12.860
   Web of Science ®Google Scholar
• Simpson EL, Parnes JR, She D, et al. Tezepelumab, an anti–thymic stromal lymphopoietin monoclonal antibody, in the treatment of moderate to severe atopic dermatitis: a randomized phase 2a clinical trial. J Am Acad Dermatol. 2019;80(4):1013–1021. doi: 10.1016/j.jaad.2018.11.059
   PubMed Web of Science ®Google Scholar
• Laidlaw TM, Menzies-Gow A, Caveney S, et al. Tezepelumab efficacy in patients with severe, uncontrolled asthma with comorbid nasal polyps in NAVIGATOR. J Asthma Allergy. 2023;16:915–932. doi: 10.2147/JAA.S413064
   PubMed Web of Science ®Google Scholar
• Leung C, Tang M, Huang BK, et al. A Novel air trapping segment score identifies opposing effects of obesity and eosinophilia on air trapping in asthma. Am J Respir Crit Care Med. 2023 Dec 19. doi: 10.1164/rccm.202305-0802OC
   Google Scholar
• Upham JW, Le Lievre C, Jackson DJ, et al. Defining a severe asthma super-responder: findings from a delphi process. J Allergy Clin Immunol Pract. 2021 Nov;9(11):3997–4004.
   PubMed Web of Science ®Google Scholar
• van Breugel M, Fehrmann RSN, Bugel M, et al. Current state and prospects of artificial intelligence in allergy. Allergy. 2023 Oct;78(10):2623–2643.
   PubMed Web of Science ®Google Scholar
• Lugogo NL, Mohan A, Akuthota P, et al. Are We Ready for asthma remission as a clinical outcome? Chest. 2023 Oct;164(4):831–834.
   PubMedGoogle Scholar
• Maldonado-Puebla M, Akenroye A, Busby J, et al. Pharmacoequity in allergy-immunology: disparities in access to medications for allergic diseases and proposed solutions in the united states and globally. J Allergy Clin Immunol Pract. 2023 Nov 10;12(2):272–280. doi: 10.1016/j.jaip.2023.11.005
   PubMed Web of Science ®Google Scholar
• Akinbami LJ, Santo L, Williams S, et al. Characteristics of asthma visits to physician offices in the united states: 2012-2015 national ambulatory medical care survey. Natl Health Stat Report. 2019 Sep; 128:1–20.
   Google Scholar
• Inselman JW, Jeffery MM, Maddux JT, et al. Trends and disparities in asthma biologic use in the united states. J Allergy Clin Immunol Pract. 2020 Feb;8(2):549–554 e1.
   PubMed Web of Science ®Google Scholar
• Sico IP, Oberle A, Thomas SM, et al. Therapeutic inertia in prescribing biologics for patients with moderate-to-severe asthma: workshop summary. Patient Prefer Adherence. 2021;15:705–712. doi: 10.2147/PPA.S303841
   PubMed Web of Science ®Google Scholar
• Nowak RM, Parker JM, Silverman RA, et al. A randomized trial of benralizumab, an antiinterleukin 5 receptor alpha monoclonal antibody, after acute asthma. Am J Emerg Med. 2015 Jan;33(1):14–20.
   PubMed Web of Science ®Google Scholar
• A Study of GSK3511294 (Depemokimab) Compared with Mepolizumab or Benralizumab in Participants with Severe Asthma with an Eosinophilic Phenotype (NIMBLE) 2024. Available from: https://clinicaltrials.gov/study/NCT04718389
   Google Scholar
• Parray HA, Shukla S, Perween R, et al. Inhalation monoclonal antibody therapy: a new way to treat and manage respiratory infections. Appl Microbiol Biotechnol. 2021 Aug;105(16–17):6315–6332.
   PubMed Web of Science ®Google Scholar
• Busse WW, Morgan WJ, Gergen PJ, et al. Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children. N Engl J Med. 2011 Mar 17;364(11):1005–1015. doi: 10.1056/NEJMoa1009705
   PubMed Web of Science ®Google Scholar
• Baccelli A, Kocwin M, Parazzini EM, et al. Long-term outcomes of combination biologic therapy in uncontrolled severe asthma: a case study. J Asthma. 2023 May;60(5):1050–1053.
   PubMed Web of Science ®Google Scholar
• Busse WW, Castro M, Casale TB. Asthma management in adults. J Allergy Clin Immunol. 2023;11(1):21–33. doi: 10.1016/j.jaip.2022.10.015
   Web of Science ®Google Scholar